Drug Trial Radar · NCT05814939
Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
Last checked: Nov 19, 2026Latest source record: Jul 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Apr 26, 2023
Primary completion
May 11, 2024
Study completion May 11, 2024
Sponsor
- Lead sponsor
- Jiangsu vcare pharmaceutical technology co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Apr 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.
Conditions
- Active Ankylosing Spondylitis
Interventions
VC005 tabletsDrug
VC005 groups repeat administration for 12 weeks
Tofacitinib Citrate TabletsDrug
Tofacitinib Citrate groups repeat administration for 12 weeks
VC005 Tablets PlaceboDrug
VC005 placebo groups repeat administration for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients achieving ASAS20Time frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.